J
J. Milburn Jessup
Researcher at National Institutes of Health
Publications - 70
Citations - 27808
J. Milburn Jessup is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Colorectal cancer & Protocol (science). The author has an hindex of 31, co-authored 69 publications receiving 25907 citations. Previous affiliations of J. Milburn Jessup include George Mason University & Deaconess Hospital.
Papers
More filters
Book
AJCC Cancer Staging Manual
Mahul B. Amin,Stephen B. Edge,Frederick L. Greene,David R. Byrd,Robert K. Brookland,Mary Kay Washington,Jeffrey E. Gershenwald,Carolyn C. Compton,Kenneth R. Hess,Daniel C. Sullivan,J. Milburn Jessup,James D. Brierley,Lauri E. Gaspar,Richard L. Schilsky,Charles M. Balch,David P. Winchester,Elliot A. Asare,Martin Madera,Donna M. Gress,Laura R. Meyer +19 more
TL;DR: Purposes and Principles of Cancer Staging and End-Results Reporting are explained.
Journal ArticleDOI
Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction
John S. Macdonald,Stephen R. Smalley,Jacqueline Benedetti,Scott A. Hundahl,Norman C. Estes,Grant N. Stemmermann,Daniel G. Haller,Jaffer A. Ajani,Leonard L. Gunderson,J. Milburn Jessup,James A. Martenson +10 more
TL;DR: This investigation investigated the effect of surgery plus postoperative (adjuvant) chemoradiotherapy on the survival of patients with resectable adenocarcinoma of the stomach or gastroesophageal junction.
Journal ArticleDOI
Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
Suzanne J. Baker,Eric R. Fearon,Janice M. Nigro,Stanley R. Hamilton,Ann C. Preisinger,J. Milburn Jessup,P vanTuinen,David H. Ledbetter,David F. Barker,Yusuke Nakamura,Ray White,Bert Vogelstein +11 more
TL;DR: The data suggest that p53 gene mutations may be involved in colorectal neoplasia, perhaps through inactivation of a tumor suppressor function of the wild-type p53 genes.
Journal ArticleDOI
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
Carmen J. Allegra,Carmen J. Allegra,J. Milburn Jessup,Mark R. Somerfield,Stanley R. Hamilton,Elizabeth H. Hammond,Daniel F. Hayes,Pamela K. McAllister,Roscoe F. Morton,Richard L. Schilsky +9 more
TL;DR: This PCO addresses the utility of KRAS gene mutation testing in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody (MoAb) therapy with cetuximab or panitumumab with a systematic review of the relevant literature.
Journal ArticleDOI
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Daniel F. Hayes,Daniel F. Hayes,Robert C. Bast,Christopher E. Desch,Herbert A. Fritsche,Nancy E. Kemeny,J. Milburn Jessup,Gershon Y. Locker,John S. Macdonald,Robert G. Mennel,Larry Norton,Peter M. Ravdin,Sheila E. Taube,Rodger J. Winn +13 more
TL;DR: The Tumor Marker Utility Grading System (TMUGS) as discussed by the authors was proposed to evaluate the clinical utility of tumor markers and to establish an investigational agenda for evaluation of new tumor markers.